- Efficacy and safety of durvalumab plus gemcitabine and cisplatin in Chinese participants with advanced biliary tract cancer: Extension cohort of the phase III, randomised, double-blind, placebo-controlled, global TOPAZ-1 studyQin, S.; Cai, J-Q.; Li, E.; Xing, B.; Zhao, L.; Dai, C.; Li, J.; Shen, Y.; Chen, Z.; Liu, L.; Lu, Z.; Zang, A.; Bai, Y.; Liang, H.; Liang, J.; Liu, X.; Wang, J.; Chen, M-H.; Miao, R.; Qu, X.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), Barcelona, SPAIN, 2023-10-20 To 2023-10-24.
- Phase 2 Trial of Adjuvant Chemotherapy With S − 1 for Node-Positive Biliary Tract Cancer (N-SOG 09)Kazuaki, Seita; Tomoki, Ebata; Takashi, Mizuno; Atsuyuki, Maeda; Ryuzo, Yamaguchi; Yasuhiro, Kurumiya; Eiji, Sakamoto; Kazuhiro, Hiramatsu; Masahiko, Ando; Masato, NaginoAnnals of Surgical Oncology, 2020, 27(7): 2348-2356.被引 3
- Treatment Modality and Trends in Survival for Gallbladder Cancer: a Population-Based StudyNoori, Akhtar-Danesh; Gileh-Gol, Akhtar-Danseh; Hsien, Seow; Saad, Shakeel; Christian, FinleyJournal of Gastrointestinal Cancer, 2021, 52(1): 256-262.
期刊论文
The Effect of Inflammatory Markers on Survival in Advanced Biliary Tract Carcinoma Treated with Gemcitabine/Oxaliplatin Regimen
1被引20阅读
